EF
HZNP

Empowered Funds’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Empowered Funds’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,864
Closed -$216K – 1350
2023
Q3 		$216K Buy
+1,864
New +$200K 0.01% 1134
2021
Q2 		– Sell
-24,558
Closed -$1.8M – 322
2021
Q1 		$1.8M Hold
24,558
– – 0.34% 104
2020
Q4 		$1.8M Buy
24,558
+4,834
+25% +$359K 0.34% 104
2020
Q3 		$1.53M Buy
+19,724
New +$1.36M 0.48% 67

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Empowered Funds's HZNP Position: Q4 2023 in Review

Empowered Funds sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 1,864 shares — an estimated $216K sold.

Empowered Funds first reported a position in HZNP in Q3 2020 and held it in 4 quarters. The position peaked at $1.8M in Q1 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Empowered Funds reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Empowered Funds sold 1,864 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $216K.
  • Empowered Funds first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 4 quarters.
  • Empowered Funds's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.8M in Q1 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Empowered Funds's 13F filing for Q4 2023, filed 14 Feb 2024.